Overton FDA nomination pulled by White House before Senate committee vote
Move to drop Trump ally and prominent abortion opponent comes a day before key Senate health committee vote The White House has dropped its nomination of Heidi Overton to lead the Food and Drug Administration, a White House official told the Guardian. Donald Trump nominated Overton – a physician and prominent abortion opponent – in August. Overton has spent most of her professional career working directly for Trump or conservative groups aligned with his agenda. Her nomination in August was seen as a move to bring a stabilizing Trump loyalist to the agency after a tumultous year under Trump’s first FDA commissioner, Marty Makary. Continue reading...

Watch this story
From Ethiopia-Eritrea Border Clashes Raise Fears of Wider Regional War, starting at 5:37 · Watch on YouTube
The White House has pulled Heidi Overton's nomination as commissioner of the Food and Drug Administration, an official there confirmed on Tuesday. The move came one day ahead of a scheduled vote in the Senate health committee on whether her nomination should go to the full chamber. NBC News and CBS News both say Axios reported the decision first.
Donald Trump nominated Overton, a physician who works as a domestic policy official in the White House, in August. The Guardian reports she has spent most of her career working directly for Trump or for conservative groups aligned with his agenda, and that the choice was viewed as a way to bring a steady loyalist to an agency unsettled during Marty Makary's tenure as Trump's first commissioner. CBS says Makary was forced out in May and that no Senate-confirmed leader has run the agency since. Kyle Diamantas is serving as acting commissioner.
Overton had trouble securing Republican backing. NBC reports the committee has 21 members and she needed 11 votes to advance, so she could not afford to lose a single Republican if every Democrat opposed her. The Guardian puts it another way: she needed all 12 Republicans on the panel, since Democrats hold 11 seats. Without committee approval, her chances of winning a vote on the Senate floor were slim.
Committee chairman Bill Cassidy, a Louisiana Republican and a doctor, had said he was undecided. The Guardian reports he earlier described her backing of Trump's plan to split up combination vaccines, such as the measles, mumps and rubella shot, as "almost disqualifying". At a September hearing he questioned her about her independence on science and whether she would resist Trump and health secretary Robert F Kennedy Jr. NBC reports he also voiced "strong concerns" and said her lack of managerial experience left her ill-prepared to run the agency. CBS says Cassidy told it late Tuesday that he still saw a possible route for her to clear the committee, that members were still talking, and that the committee had not told the White House it lacked the votes. Two sources told CBS the White House passed on its decision Tuesday evening while efforts to count Republican votes were continuing.
Other Republicans were noncommittal. Susan Collins of Maine told NBC last week that she had "not taken a position" and wanted answers on several matters. Lisa Murkowski of Alaska would not say how she would vote; at the hearing she faulted Overton for failing to state a clear position on the abortion pill mifepristone. CBS reports that some lawmakers and administration allies were skeptical, in part because of her testimony on mifepristone and her role in carrying out Trump's pro-vaping policies.
Abortion was a central issue because the FDA regulates medication abortion. In a 2023 policy brief for the America First Policy Institute, where she was chief policy officer, Overton argued Congress should tightly regulate mifepristone "to protect women and children" and criticized federal policies permitting abortion pills to be sent by mail. Mini Timmaraju, president and CEO of Reproductive Freedom for All, welcomed the withdrawal. She said Overton was a "serious threat" to medication abortion access, and that the group would keep fighting if Republicans try to push through another nominee.
What happens next is unsettled. CBS cites a source saying the White House had started speaking with other candidates, some of whom could take the job in an acting role without Senate confirmation. Two sources told CBS that Kansas Senator Roger Marshall, a doctor who lost his reelection bid this month to Democrat Adam Hamilton, is pursuing the job. CBS describes Overton as close to Susie Wiles, who left her post as White House chief of staff earlier this month.
Republicans are trying to confirm Trump's pending nominees before Democrats take over the Senate in January, so any confirmation would have to happen in a narrow window. Asked on Sunday's "Face the Nation" whether Republicans would pursue a permanent commissioner, Cassidy said perfection was not on offer. He asked whether the party wanted "a series of short-term administrators" likely to be more swayed by the secretary, instead of a permanent figure who could build some independence.
Spotted an error? Report it · Editorial standards · Corrections policy
Source & verification
VerifiedReported from Guardian US Politics.
Also written from and checked against reports by NBC News Politics and CBS News Politics.
Get breaking news alerts and the Morning Briefing
Verified stories in your inbox, every one linked to its sources. All newsletters →


